30 results on '"Schönland, Stefan"'
Search Results
2. Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP‐EBMT study
3. Quality of Life and Symptoms Among Patients With Relapsed/Refractory AL Amyloidosis Treated With Ixazomib‐Dexamethasone Versus Physician's Choice
4. Statin‐based endothelial prophylaxis and outcome after allogeneic stem cell transplantation
5. Concurrent light chain amyloidosis and proximal tubulopathy: Insights into different aggregation behavior—A case report
6. Health‐related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study
7. Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019
8. Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosis
9. Submyeloablative total body irradiation‐based conditioning and allogeneic stem cell transplantation in high‐risk myeloma with early progression after up‐front autologous transplantation
10. Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow‐up
11. Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement
12. Daratumumab, lenalidomide, and dexamethasone in systemic light‐chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21
13. Prognostic impact of early‐versus‐late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT
14. Ruxolitinib is effective in the treatment of a patient with refractory T‐ALL
15. Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression
16. Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID‐19 pandemic
17. Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis
18. Treosulfan conditioning for allogeneic transplantation in multiple myeloma – improved overall survival in first line haematopoietic stem cell transplantation – a large retrospective study by the Chronic Malignancies Working Party of the EBMT
19. Conditioning‐based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991‐2012) on behalf of EBMT CMWP
20. CD7 is expressed on a subset of normal CD34-positive myeloid precursors
21. Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma
22. Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice
23. Common Fibril Structures Imply Systemically Conserved Protein Misfolding Pathways In Vivo
24. Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis
25. Polymorphismus von Amyloidfibrillen in vivo
26. Polymorphism of Amyloid Fibrils In Vivo
27. Potential therapeutic targets in plasma cell disorders: A flow cytometry study
28. Modified body mass index and time interval between diagnosis and operation affect survival after liver transplantation for hereditary amyloidosis: a single‐center analysis
29. Statin-based endothelial prophylaxis and outcome after allogeneic stem cell transplantation.
30. Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the Acute Leukemia Working Party of the EBMT.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.